Celldex Therapeutics
Stock Forecast, Prediction & Price Target
Celldex Therapeutics (CLDX) stock Price Target by analysts
$62
Potential upside: 201.26%
Celldex Therapeutics price prediction
What is Celldex Therapeutics stock analysts` prediction?
Celldex Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for Celldex Therapeutics in the last 3 months, the avarage price target is $62, with a high forecast of $NaN. The average price target represents a 201.26% change from the last price of $20.58.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Celldex Therapeutics stock Price Target by analysts
Full breakdown of analysts given Celldex Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Joseph Pantginis H.C. Wainwright | 0% 0/1 | 10 months ago | $80 288.72% upside | $27.12 | StreetInsider | Previous targets (0) |
Derek Archila Wells Fargo | 50% 1/2 | 12 months ago | $44 113.79% upside | $36.02 | TheFly | Previous targets (1) |
Alex Thompson Stifel Nicolaus | 0% 0/1 | about 1 year ago | $58 181.82% upside | $34.91 | TheFly | Previous targets (0) |
Derek Archila Wells Fargo | 50% 1/2 | almost 2 years ago | $27 31.19% upside | $25.78 | StreetInsider | Previous targets (1) |
Unknown Guggenheim | N/A | almost 3 years ago | $63 206.12% upside | $39.89 | Benzinga | N/A |
Celldex Therapeutics Financial Estimates
Celldex Therapeutics Revenue Estimates
Celldex Therapeutics EBITDA Estimates
Celldex Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $4.65M N/A | $2.35M -49.32% | $6.88M 192.02% | Avg: $3.82M Low: $1.78M High: $6.68M avg. -44.42% | Avg: $2.04M Low: $706.31K High: $3.57M avg. -46.66% | Avg: $89.56M Low: $31.01M High: $156.87M avg. 4290.52% | Avg: $466.82M Low: $161.62M High: $817.65M avg. 421.20% |
Net Income
% change YoY
| $-70.51M N/A | $-122.78M -74.13% | $-141.42M -15.18% | Avg: $-198.25M Low: $-166.18M High: $-118.21M avg. -40.18% | Avg: $-229.8M Low: $-221.41M High: $-110.94M avg. -15.91% | Avg: $-168.36M Low: $-332.84M High: $-25.27M avg. 26.73% | Avg: $31.37M Low: $4.70M High: $62.01M avg. 118.63% |
EBITDA
% change YoY
| $-67.55M N/A | $-101.86M -50.78% | $-139.03M -36.48% | Avg: $-3.82M Low: $-6.68M High: $-1.78M avg. 97.24% | Avg: $-2.04M Low: $-3.57M High: $-706.31K avg. 46.66% | Avg: $-89.56M Low: $-156.87M High: $-31.01M avg. -4290.52% | Avg: $-466.82M Low: $-817.65M High: $-161.62M avg. -421.20% |
EPS
% change YoY
| -$1.64 N/A | -$2.62 -59.75% | -$2.92 -11.45% | Avg: -$2.86 Low: -$3.43 High: -$2.44 avg. 2.01% | Avg: -$3.22 Low: -$4.57 High: -$2.29 avg. -12.46% | Avg: -$3.48 Low: -$6.87 High: -$0.52 avg. -7.98% | Avg: $0.65 Low: $0.1 High: $1.28 avg. 118.63% |
Operating Expenses
% change YoY
| $73.79M N/A | $109.45M 48.31% | $161.42M 47.48% | Avg: $20.42M Low: $9.51M High: $35.67M avg. -87.34% | Avg: $10.89M Low: $3.77M High: $19.08M avg. -46.66% | Avg: $478.29M Low: $165.60M High: $837.74M avg. 4290.52% | Avg: $2.49B Low: $863.12M High: $4.36B avg. 421.20% |
FAQ
What is Celldex Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 22.31% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -166.18M, average is -198.25M and high is -118.21M.
What is Celldex Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1155.15% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $1.78M, average is $3.82M and high is $6.68M.
What is Celldex Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 25.04% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$3.43, average is -$2.86 and high is $-2.44.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Celldex Therapeutics stock. The most successful analyst is Joseph Pantginis.